fbpx

Year

2012
Lundbeckfonden indkalder ansøgninger til fem sundhedsvidenskabelige og to naturvidenskabelige fellowships til særligt lovende unge forskere og deres forskergrupper.
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has entered into an exclusive distribution agreement with Chiesi Farmaceutici S.p.A, a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, for the commercialization and distribution of its novel formulation immunosuppressant drug candidate LCP-Tacro in certain countries, including Europe, Turkey and...
Agreement will support future clinical trials of Celladon’s product candidate MYDICAR® for the treatment of advanced heart failure.   Lonza, a global leader in the field of viral therapy manufacturing, and Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that they have entered into...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa proof-of-concept study investigating APD403 for the prevention of acute nausea & vomiting in cancer patients receiving the highly emetogenic chemotherapy drug cisplatin. Although a number of anti-emetics are available on the market, these...
Patienter med type 2-diabetes har i deres tarmflora en overvægt af potentielt sygdomsfremkaldende bakterier og et underskud af de bakterier, som er vigtige for vores sundhed og velbefindende, viser ny forskning, som netop er blevet offentliggjort i Nature. Den ny viden kan måske på sigt blive et vigtigt redskab til at forebygge og behandle sygdommen.
‘Evolve’ Study Will Assess Safety and Tolerability of Unique Anti-Cancer Agent, ColoAd1   (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial of the systemically available oncolytic vaccine ColoAd1, a highly...
Vi bruger næsten 1/3 af livet på at sove, men hvorfor er det så vigtigt at få lukket øjnene i 7-8 timer hver nat? Lundbeckfond Lectures går denne gang bag om søvn og drømme og afdækker, hvorfor søvn er så vigtigt. Aftenens to søvnforskere klinisk professor og overlæge Poul Jennum og seniorforsker Birgitte Rahbek Kornum...
  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that FierceBiotech named Celladon as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.   “You don't...
Agreement Covers Distribution Rights of CERAMENT in United States and Canada BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the signing of a multi-year exclusive distribution agreement with Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products. Under...
Velkommen til en aften hvor vi bevæger os ud i universet og kigger nærmere på det mystiske og usynlige mørke stof, som udgør 80 % af vores univers. Mørkt stof er uhyre svært at studere og at finde ud af, hvad er for noget, fordi det er umuligt at fange og holde fast. Men det...
1 2 3 4 5 8

Nyheder

Maude er blevet den stereotype migræne-patient – men det er ikke helt virkelighedsdækkende
31. juli 2020
Urgammelt DNA kaster en ’videnskabelig håndgranat’ ind i diskussionen om menneskets ankomst til Amerika
23. juli 2020
Danske forskere kortlægger central sygdomsmekanisme – og beskriver et helt nyt protein
20. juli 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge